DiaMedica raises $30M in private placement at $3.92/share for DM199 development

DiaMedica Therapeutics Inc.

Gross proceeds of $30M from sale of 7,653,060 common shares at $3.92 each.
Closing expected September 28, 2021; net proceeds to fund DM199 clinical development including ReMEDy2 trial.
Ten accredited investors participate; shares unregistered but resale registration to be filed with SEC.
Funds also allocated to working capital and general corporate purposes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.